[go: up one dir, main page]

ES2534582T3 - Procedimiento para diagnosticar una enfermedad neurodegenerativa - Google Patents

Procedimiento para diagnosticar una enfermedad neurodegenerativa Download PDF

Info

Publication number
ES2534582T3
ES2534582T3 ES10182499.3T ES10182499T ES2534582T3 ES 2534582 T3 ES2534582 T3 ES 2534582T3 ES 10182499 T ES10182499 T ES 10182499T ES 2534582 T3 ES2534582 T3 ES 2534582T3
Authority
ES
Spain
Prior art keywords
disease
alzheimer
expression
level
diagnose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10182499.3T
Other languages
English (en)
Inventor
Maria Zellner
Rudolf Oehler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Randox Laboratories Ltd
Original Assignee
Randox Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Randox Laboratories Ltd filed Critical Randox Laboratories Ltd
Application granted granted Critical
Publication of ES2534582T3 publication Critical patent/ES2534582T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
    • G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
    • G01N2333/90638—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general with a definite EC number (1.4.3.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Procedimiento para el diagnóstico de la enfermedad de Alzheimer, que comprende la medición del nivel de expresión de la proteína de la glutatión S-transferasa de tipo silvestre identificada por el número de acceso de SwissProt P78417 en una muestra de plaquetas aisladas de una persona que se sospecha que tiene la enfermedad de Alzheimer, y determinar si el nivel de la expresión está alterado en comparación con un control, en donde un incremento del nivel de expresión de la proteína de la glutatión S-transferasa de tipo silvestre identificada por el número de acceso de SwissProt P78417 cuando se compara con un control sano sin enfermedad indica la presencia de la enfermedad de Alzheimer.
ES10182499.3T 2005-06-17 2006-06-19 Procedimiento para diagnosticar una enfermedad neurodegenerativa Active ES2534582T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0512401.1A GB0512401D0 (en) 2005-06-17 2005-06-17 Method
GB0512401 2005-06-17

Publications (1)

Publication Number Publication Date
ES2534582T3 true ES2534582T3 (es) 2015-04-24

Family

ID=34855743

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10182499.3T Active ES2534582T3 (es) 2005-06-17 2006-06-19 Procedimiento para diagnosticar una enfermedad neurodegenerativa
ES10183043.8T Active ES2533086T3 (es) 2005-06-17 2006-06-19 Método para el diagnóstico de una enfermedad neurodegenerativa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10183043.8T Active ES2533086T3 (es) 2005-06-17 2006-06-19 Método para el diagnóstico de una enfermedad neurodegenerativa

Country Status (5)

Country Link
US (2) US20080318229A1 (es)
EP (8) EP2293073B1 (es)
ES (2) ES2534582T3 (es)
GB (1) GB0512401D0 (es)
WO (1) WO2006134390A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009074331A2 (en) * 2007-12-11 2009-06-18 Julius-Maximilians-Universität Würzburg Early and differential diagnosis test for alzheimer's disease
DE102007062847A1 (de) * 2007-12-21 2009-12-31 Protagen Ag Markersequenzen für neurodegenerative Erkrankungen und deren Verwendung
CN101978269A (zh) 2008-01-18 2011-02-16 哈佛大学校长及研究员协会 在体液中检测疾病或病症标志的方法
JP5755149B2 (ja) * 2009-01-26 2015-07-29 エレクトロフォレティクス リミテッドＥｌｅｃｔｒｏｐｈｏｒｅｔｉｃｓ Ｌｉｍｉｔｅｄ 方法
GB0906458D0 (en) 2009-04-15 2009-05-20 Randox Lab Ltd Macromolecules for diagnosis and prognosis
GB0921447D0 (en) 2009-12-04 2010-01-20 Randox Lab Ltd Assay
US20130316338A1 (en) * 2010-06-29 2013-11-28 The United States Government As Represented By The Department Of Veterans Affairs CCR6 As A Biomarker of Alzheimer's Disease
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
WO2012012725A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting diseases or conditions using phagocytic cells
KR20130041961A (ko) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액에서 질환 또는 상태의 특징을 검출하는 방법
US20130184178A1 (en) 2010-07-23 2013-07-18 President And Fellows Of Harvard College Methods of Detecting Autoimmune or Immune-Related Diseases or Conditions
GB201104286D0 (en) * 2011-03-15 2011-04-27 Randox Lab Ltd Glutathione S-transferase omega 1 wild type specific antibody
WO2012175674A1 (en) * 2011-06-24 2012-12-27 Baden-Württemberg Stiftung Ggmbh Diagnosis and/or prognosis of a neurodegenerative disease
GB201122227D0 (en) 2011-12-23 2012-02-01 Randox Lab Ltd MAO-B inhibitors derived from the one-carbon cycle
US20150141260A1 (en) 2012-06-15 2015-05-21 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
CN104603289A (zh) 2012-06-15 2015-05-06 哈里·斯泰利 检测疾病或病状的方法
GB201212084D0 (en) 2012-07-06 2012-08-22 Randox Lab Ltd Tropomyosin isoforms related to alzheimers disease and mild cognitive impairment
GB201217688D0 (en) * 2012-10-03 2012-11-14 Randox Lab Ltd Method
GB2511525A (en) * 2013-03-05 2014-09-10 Randox Teoranta Methods and Compositions for the Diagnosis of Alzheimer's Disease
EP3385717A3 (en) 2013-03-09 2018-10-24 Harry Stylli Methods of detecting prostate cancer
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
GB201320164D0 (en) * 2013-11-15 2014-01-01 Randox Lab Ltd Sample preparation method for analysis of platelet proteins
WO2016040843A1 (en) 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
CA3067294A1 (en) * 2017-06-16 2018-12-20 Centre Hospitalier Regional Et Universitaire De Lille (Chru) Process for preparing a pooled human platelet lysate, pooled human platelet lysate and its use for treating neurological disorders
CN114966048A (zh) * 2022-05-12 2022-08-30 东南大学 血小板AβPP比值在阿尔茨海默病筛查中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756479A (en) * 1994-12-29 1998-05-26 Research Development Foundation Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase
EP0874242B2 (en) 1997-04-21 2009-06-03 Randox Laboratories Ltd. Device and apparatus for the simultaneous detection of multiple analytes
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
CA2335656A1 (en) * 1998-07-31 2000-02-10 Incyte Pharmaceuticals, Inc. Human cytoskeletal proteins
CA2404233A1 (en) * 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030064411A1 (en) * 2000-12-08 2003-04-03 Herath Herath Mudiyanselage Athula Chandrasiri Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of Alzheimer's disease
DE10100121A1 (de) * 2001-01-03 2002-08-01 Henkel Kgaa Verfahren zur Bestimmung des Hautstreß oder der Hautalterung in vitro
US7482117B2 (en) * 2002-12-20 2009-01-27 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
US20070218513A1 (en) * 2003-10-16 2007-09-20 Novartis Ag Differentially Expressed Genes Related to Coronary Artery Disease
TWI281473B (en) * 2003-12-19 2007-05-21 Ind Tech Res Inst Biomarkers for liver diseases and method for using same
CA2557181A1 (en) * 2004-02-26 2005-09-09 Ohio University Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells
WO2005110460A2 (en) * 2004-04-29 2005-11-24 Ohio University Diagnosis and treatment methods related to aging, especially in muscle (14.1)
JP2008506415A (ja) * 2004-07-19 2008-03-06 ユニバーシティー オブ ロチェスター 神経変性疾患の生物マーカー
EP1775590A1 (en) * 2005-10-11 2007-04-18 Laboratorios S.A.L.V.A.T., S.A. Non-invasive in vitro method to detect transitional cell carcinoma of the bladder

Also Published As

Publication number Publication date
EP2287618A3 (en) 2011-05-25
EP3031823B1 (en) 2018-12-19
US20160161508A1 (en) 2016-06-09
EP2293075A2 (en) 2011-03-09
EP2293073B1 (en) 2014-12-31
EP2293074A3 (en) 2011-05-04
EP2293075A3 (en) 2011-05-04
EP2293073A2 (en) 2011-03-09
EP3031823A1 (en) 2016-06-15
WO2006134390A2 (en) 2006-12-21
GB0512401D0 (en) 2005-07-27
EP2287617A2 (en) 2011-02-23
EP1891445A2 (en) 2008-02-27
EP2293074A2 (en) 2011-03-09
EP2287617A3 (en) 2011-05-18
EP2287618A2 (en) 2011-02-23
WO2006134390A3 (en) 2007-04-19
ES2533086T3 (es) 2015-04-07
EP2293073A3 (en) 2011-09-14
EP2339348A2 (en) 2011-06-29
EP2287617B1 (en) 2015-08-12
EP2339348A3 (en) 2011-09-14
EP2287618B1 (en) 2014-12-31
EP2339348B1 (en) 2015-01-21
US20080318229A1 (en) 2008-12-25

Similar Documents

Publication Publication Date Title
ES2534582T3 (es) Procedimiento para diagnosticar una enfermedad neurodegenerativa
ATE456055T1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
ATE533061T1 (de) Verfahren zur diagnose bakterieller infektionen
Montecucco et al. Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4
WO2009132058A3 (en) Levels of bcma protein expression on b cells and use in diagnostic methods
BR112012025517A2 (pt) ____________________________________________________________ anticorpo que reconhece fator inibidor de leucemia (lif) humano e uso de anti-lif anticorpos no tratamento de doenças associadas a proliferação celular não desejada
ATE511651T1 (de) Transglutaminase 6 als diagnostischer indikator für autoimmunerkrankungen
ATE534038T1 (de) Neurodegenerative marker für alzheimer-krankheit
BR0108802A (pt) Métodos de diagnóstico e terapêuticos para glaucoma
EP2359139A4 (en) DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES BY TARGETING AUTOIMMUNE BELL CELLS ("CBAI")
WO2018038352A3 (ko) 치매진단용 자가항체 바이오마커 및 이를 이용한 치매진단 방법
ATE451475T1 (de) Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben
AR054479A1 (es) Metodo para diagnosticar l a enfermedad de alzheimer
Nissen et al. Tumstatin fragment selectively inhibits neutrophil infiltration in experimental asthma exacerbation
WO2010084327A3 (en) Methods
Kim et al. Development of nutrition screening index for hospitalized patients
Schreiber et al. A Caenorhabditis elegans p38 MAP kinase pathway mutant protects from dopamine, methamphetamine, and MDMA toxicity
ATE406579T1 (de) Verfahren zur diagnose von tumoren
BR0015055A (pt) Método de aumento estimulação ou potencialização da diferenciação de células t, método de tratamento de uma doença mediada por th1 em um mamìfero, método de prevenir, inibir ou atenuar a diferenciação de céluas t, método de tratamento de uma doença mediada por th2, em um mamìfero, método de determinação da presença de polipeptìdeo tccr em uma célula, método de diagnóstico de doenças mediadas por th1 ou mediadas por th2 em um mamìfero, método de identificação de compostos capazes de inibir a expressão de polipeptìdeos tccr e método para identificação de compostos capazes de inibir a atividade biológica de polipeptìdeo tccr, uso de antagonistas e agonistas de polipeptìdeos tccr
RU2014152876A (ru) Изоформы тропомиозина, связанные с болезнью альцгеймера и умеренными когнитивными нарушениями
BRPI0417291A (pt) pano industrial, método para a formação de uma pano industrial e estrutura de pano industrial intermediário
IN2014MN01759A (es)
MX2015013851A (es) Uso de auto-anticuerpos contra citoqueratina 19 para el diagnostico de cáncer de pulmon.
Atiyah et al. Evaluation of Salivary and Serum Oxidative Stress and Neuronal Damage Markers as Potential Parameters in Prediction of Ischemic Stroke from Stroke-Related Risk Factors
Lewis Drifting representations